HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 424 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,952,558 | +84.3% | 37,291 | +43.2% | 0.00% | +100.0% |
| Q1 2024 | $1,059,389 | +33.1% | 26,042 | +20.9% | 0.00% | 0.0% |
| Q4 2023 | $795,897 | +24.2% | 21,534 | +28.3% | 0.00% | 0.0% |
| Q3 2023 | $641,034 | +31.9% | 16,781 | +24.6% | 0.00% | 0.0% |
| Q2 2023 | $485,863 | +77.0% | 13,470 | +179.2% | 0.00% | – |
| Q4 2022 | $274,486 | +44.5% | 4,824 | -54.9% | 0.00% | -100.0% |
| Q4 2019 | $190,000 | -63.7% | 10,692 | -68.3% | 0.00% | -50.0% |
| Q3 2019 | $523,000 | -9.7% | 33,692 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $579,000 | -7.1% | 33,692 | -12.9% | 0.00% | 0.0% |
| Q1 2019 | $623,000 | -32.6% | 38,692 | -38.8% | 0.00% | -50.0% |
| Q4 2018 | $924,000 | -20.3% | 63,192 | -0.9% | 0.00% | 0.0% |
| Q3 2018 | $1,159,000 | -6.9% | 63,792 | -13.6% | 0.00% | -20.0% |
| Q2 2018 | $1,245,000 | -25.0% | 73,792 | -13.0% | 0.01% | -28.6% |
| Q1 2018 | $1,661,000 | -6.5% | 84,792 | -3.3% | 0.01% | -12.5% |
| Q4 2017 | $1,776,000 | +14.7% | 87,682 | -1.6% | 0.01% | +14.3% |
| Q3 2017 | $1,548,000 | +5.3% | 89,092 | -22.3% | 0.01% | 0.0% |
| Q2 2017 | $1,470,000 | +0.1% | 114,667 | +1.2% | 0.01% | -12.5% |
| Q1 2017 | $1,468,000 | +40.2% | 113,284 | -16.5% | 0.01% | +33.3% |
| Q4 2016 | $1,047,000 | -16.4% | 135,750 | +1.9% | 0.01% | -25.0% |
| Q3 2016 | $1,253,000 | +5.4% | 133,250 | -20.4% | 0.01% | -11.1% |
| Q2 2016 | $1,189,000 | -18.1% | 167,350 | -8.2% | 0.01% | -18.2% |
| Q1 2016 | $1,451,000 | -42.9% | 182,350 | +3.4% | 0.01% | -45.0% |
| Q4 2015 | $2,542,000 | +38.8% | 176,350 | +4.8% | 0.02% | +25.0% |
| Q3 2015 | $1,832,000 | -37.6% | 168,350 | +20.0% | 0.02% | -40.7% |
| Q2 2015 | $2,934,000 | +560.8% | 140,350 | +351.3% | 0.03% | +575.0% |
| Q1 2015 | $444,000 | +43.2% | 31,100 | -3.1% | 0.00% | +33.3% |
| Q4 2014 | $310,000 | -44.7% | 32,100 | -47.9% | 0.00% | -57.1% |
| Q3 2014 | $561,000 | -6.7% | 61,600 | +1.3% | 0.01% | -12.5% |
| Q2 2014 | $601,000 | -20.6% | 60,800 | +2.0% | 0.01% | -27.3% |
| Q1 2014 | $757,000 | -15.7% | 59,600 | -0.5% | 0.01% | -26.7% |
| Q4 2013 | $898,000 | +164.1% | 59,900 | +94.5% | 0.02% | +114.3% |
| Q3 2013 | $340,000 | +38.8% | 30,800 | 0.0% | 0.01% | +16.7% |
| Q2 2013 | $245,000 | – | 30,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
| BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
| DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
| SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
| First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
| Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
| Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
| Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |